News

Article

FDA Guidance on ANDA and 505(b)(2) Applications

The new guidance was issued to assist applicants in determining which abbreviated pathway to take for submitting marketing applications.

FDA issued guidance on May 9, 2019 for applicants submitting abbreviated approval marketing applications. The guidance was issued to assist applicants in determining which abbreviated approval pathway to choose under the Federal Food, Drug, and Cosmetic Act (FD&C Act): an abbreviated new drug application (ANDA) or a 505(b)(2) application.

The guidance details the criteria for submitting applications under the two pathways. It also provides considerations for determining the more appropriate application submitted under section 505(j) or pursuant to section 505(b)(2) of the FD&C Act. The guidance offers direction to potential applicants on requesting assistance from FDA in making this determination.

Specifically, the guidance discusses duplicate applications, petitioned ANDAs, and bundling of multiple products. Scientific considerations, such as types of studies and data, are discussed. API evaluations and formulation differences are also addressed.

Source: FDA

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More